Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR

References

• Yao JC, Hassan M, Phan A, et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72
   PubMed Web of Science ®Google Scholar
• Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1-18, vii
   PubMed Web of Science ®Google Scholar
• Frilling A, Akerstrom G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer 2012;19:R163-85
   PubMed Web of Science ®Google Scholar
• Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg 1996;20:126-31
   PubMed Web of Science ®Google Scholar
• Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:151-60
   PubMed Web of Science ®Google Scholar
• Kaehler HJ, Heilmeyer L. [Clinical aspects and pathophysiology of carcinoid and carcinoid syndrome with special reference to the pharmacology of 5-hydroxytryptamine]. Ergeb Inn Med Kinderheilkd 1961;16:292-559
   PubMedGoogle Scholar
• Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res 2003;22:517-30
   PubMed Web of Science ®Google Scholar
• DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s Cancer: principles & practice of oncology review. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2008
   Google Scholar
• Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017;18:525-34
   PubMed Web of Science ®Google Scholar
• O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-6.
   PubMed Web of Science ®Google Scholar
• Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol 2013;40:56-68.
   PubMed Web of Science ®Google Scholar
• Strosberg JR. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. Endocr Pract 2014;20:167-75
   PubMed Web of Science ®Google Scholar
• Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. W J Gastroenterol 2015;21:1945-55.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Weber J, Feldman M, et al. Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. Gastrointest Cancer Res 2013;6:81-5
   PubMedGoogle Scholar
• Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist 2014;19:930-6
   PubMed Web of Science ®Google Scholar
• Broder MS, Chang E, Cherepanov D, et al. The cost impact of non-infectious diarrhea in patients with carcinoid syndrome. North American Neuroendocrine Tumor Society (NANETS) Symposium. Austin, TX: Pancreas 2016;45:472
   Google Scholar
• Novartis unpublished data on file: health resource utilization and costs of patients with carcinoid syndrome-related flushing; 2015
   Google Scholar
• Broder MS, Chang E, Romanus D, et al. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. W J Gastroenterol 2016;22:2118-25
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer price index for all urban consumers (CPI-U): medical care. Washington, DC: Bureau of Labor Statistics; 2014
   Google Scholar
• Ruxton GD. The unequal variance t-test is an underused alternative to student’s t-test and the Mann–Whitney U test. Behav Ecol 2006;17:688-90
   Web of Science ®Google Scholar
• Neuhäuser M. Two-sample tests when variances are unequal. Animal Behav 2002;63:823-5
   Web of Science ®Google Scholar
• Bureau of Labor Statistics. May 2014 national occupational employment and wage estimates. Washington, DC: US Bureau of Labor Statistics; 2015. http://www.bls.gov/oes/2014/may/oes_nat.htm. Accessed June 6, 2016
   Google Scholar
• Chadha MK, Lombardo J, Mashtare T, et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res 2009;29:4127-30
   PubMed Web of Science ®Google Scholar
• Ferolla P, Faggiano A, Grimaldi F, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest 2012;35:326-31
   PubMed Web of Science ®Google Scholar
• Chuang CC, Bhurke S, Chen SY, et al. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study. J Med Econ 2015;18:126-36
   PubMed Web of Science ®Google Scholar
• Peeters M, Van den Brande J, Francque S. Diarrhea and the rationale to use Sandostatin. Acta Gastroenterol Belg 2010;73:25-36
   PubMed Web of Science ®Google Scholar
• Beaumont JL, Cella D, Phan AT, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 2012;41:461-6
   PubMed Web of Science ®Google Scholar